Switch over from intravenous to oral therapy: A concise overview
Jissa Maria Cyriac, Emmanuel James, Jissa Maria Cyriac, Emmanuel James
Abstract
Majority of the patients admitted to a hospital with severe infections are initially started with intravenous medications. Short intravenous course of therapy for 2-3 days followed by oral medications for the remainder of the course is found to be beneficial to many patients. This switch over from intravenous to oral therapy is widely practiced in the case of antibiotics in many developed countries. Even though intravenous to oral therapy conversion is inappropriate for a patient who is critically ill or who has inability to absorb oral medications, every hospital will have a certain number of patients who are eligible for switch over from intravenous to oral therapy. Among the various routes of administration of medications, oral administration is considered to be the most acceptable and economical method of administration. The main obstacle limiting intravenous to oral conversion is the belief that oral medications do not achieve the same bioavailability as that of intravenous medications and that the same agent must be used both intravenously and orally. The advent of newer, more potent or broad spectrum oral agents that achieve higher and more consistent serum and tissue concentration has paved the way for the popularity of intravenous to oral medication conversion. In this review, the advantages of intravenous to oral switch over therapy, the various methods of intravenous to oral conversion, bioavailability of various oral medications for the switch over program, the patient selection criteria for conversion from parenteral to oral route and application of intravenous to oral switch over through case studies are exemplified.
Keywords: Economic impact; intravenous to oral; parenteral medication; switch over.
Conflict of interest statement
Conflict of Interest: None declared.
References
- Kuper KM. Text Book of Competence Assessment Tools for Health-System Pharmacies. 4th ed. ASHP: 2008. Intravenous to oral therapy conversion; pp. 347–60.
- Lee SL, Azmi S, Wong PS. Clinicians' knowledge, beliefs and acceptance of intravenous-to-oral antibiotic switching, Hospital Pulau Pinang. Med J Malaysia. 2012;67:190–8.
- Sevinc F, Prins JM, Koopmans RP, Langendijk PN, Bossuyt PM, Dankert J, et al. Early switch from intravenous to oral antibiotics: Guidelines and implementation in a large teaching hospital. J Antimicrob Chemother. 1999;43:601–6.
- The pursuit of responsible use of medicines: Sharing and learning from country experiences. [Last accessed on 2013 Jun 29; Last updated on 2013 Jun 22]. Available from:
- World Health Day 2011 . Antibiotic resistance: No action today, no cure tomorrow. [Last accessed on 2013 Jun 29]. Available from: .
- Fischer MA, Solomon DH, Teich JM, Avorn J. Conversion from intravenous to oral medications: Assessment of a computerized intervention for hospitalized patients. Arch Intern Med. 2003;163:2585–9.
- Cunha BA. Intravenous-to oral antibiotic switch therapy. A cost-effective approach. Postgrad Med. 1997;101:111–2.
- McLaughlin CM, Bodasing N, Boyter AC, Fenelon C, Fox JG, Seaton RA. Pharmacy-implemented guidelines on switching from intravenous to oral antibiotics: An intervention study. QJM. 2005;98:745–52.
- Gyawali S, Shankar PR, Saha A, Mohan L. Study of prescription of injectable drugs and intravenous fluids to inpatients in a teaching hospital in Western Nepal. Mcgill J Med. 2009;12:13–20.
- Palanisamy A, Narmatha MP, Rajendran NN, Rajalingam B, Sriram S. Conversion of intravenous-to-oral antimicrobial therapy in South Indian population. IJRPBS. 2011;2:1258–60.
- Banko H, Goldwater SH, Adams E. Smoothing the path for intravenous (IV) to oral (PO) conversion: Where have we come in 11 years? Hosp Pharm. 2009;44:959–67.
- Cunha BA. Oral versus IV treatment for catheter-related bloodstream infections. Emerg Infect Dis. 2007;13:1800–1.
- File TM, Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997;41:1965–72.
- Castro-Guardiola A, Viejo-Rodríguez AL, Soler-Simon S, Armengou-Arxé A, Bisbe-Company V, Peñarroja-Matutano G, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: A randomized controlled trial. Am J Med. 2001;111:367–74.
- Jensen KM, Paladino JA. Cost-Effectiveness of abbreviating the duration of intravenous antibacterial therapy with oral fluoroquinolones. Pharmacoeconomics. 1997;11:64–74.
- Galanter W, Liu XF, Lambert BL. Analysis of computer alerts suggesting oral medication use during computerized order entry of iv. medications. Am J Health Syst Pharm. 2010;67:1101–5.
- Hamilton-Miller JM. Switch therapy: The theory and practice of early change from parenteral to non-parenteral antibiotic administration. Clin Microbiol Infect. 1996;2:12–9.
- NHS Grampian medicines management. [Last accessed on 2013 Jun 29; Last updated on 2012 Jun]. Available from: .
- Wetzstein GA. Intravenous to oral (iv: po) anti-infective conversion therapy. Cancer Control. 2000;7:170–6.
- IV to oral conversion program. [Last accessed on 2013 Jun 29; Last updated on 2013 Jun 20]. Available from: .
- Zamin MT, Pitre MM, Conly JM. Development of an intravenous-to-oral route conversion program for antimicrobial therapy at a Canadian tertiary care health facility. Ann Pharmacother. 1997;31:564–70.
- Lee RW, Lindstrom ST. Early switch to oral antibiotics and early discharge guidelines in the management of community-acquired pneumonia. Respirology. 2007;12:111–6.
- Janknegt R, van der Meer JW. Sequential therapy with intravenous and oral cephalosporins. J Antimicrob Chemother. 1994;33:169–77.
- Cunha BA. Text book of essentials of antibiotic prescribing. 10th ed. USA: Jones and Barlett Publishers; 2011. pp. 10–25.
Source: PubMed